Kestra Private Wealth Services LLC Increases Position in McKesson Corporation $MCK

Kestra Private Wealth Services LLC lifted its position in shares of McKesson Corporation (NYSE:MCK) by 37.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 3,213 shares of the company’s stock after purchasing an additional 883 shares during the period. Kestra Private Wealth Services LLC’s holdings in McKesson were worth $2,636,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of MCK. Brighton Jones LLC increased its stake in McKesson by 46.3% in the 4th quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock worth $1,438,000 after buying an additional 798 shares in the last quarter. Caxton Associates LLP purchased a new position in shares of McKesson in the first quarter valued at about $233,000. Sivia Capital Partners LLC boosted its stake in shares of McKesson by 77.9% in the second quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock worth $502,000 after acquiring an additional 300 shares during the period. Treasurer of the State of North Carolina boosted its stake in shares of McKesson by 0.9% in the second quarter. Treasurer of the State of North Carolina now owns 58,623 shares of the company’s stock worth $42,958,000 after acquiring an additional 508 shares during the period. Finally, Osterweis Capital Management Inc. purchased a new stake in shares of McKesson during the second quarter worth about $166,000. Institutional investors own 85.07% of the company’s stock.

Insider Buying and Selling at McKesson

In other news, Director Maria Martinez sold 349 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $939.87, for a total value of $328,014.63. Following the sale, the director directly owned 301 shares in the company, valued at $282,900.87. The trade was a 53.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Leann B. Smith sold 190 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total transaction of $179,550.00. Following the sale, the executive vice president owned 2,989 shares in the company, valued at $2,824,605. This represents a 5.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,592 shares of company stock worth $3,518,555 in the last ninety days. Company insiders own 0.08% of the company’s stock.

McKesson Trading Down 1.4%

Shares of McKesson stock opened at $823.68 on Thursday. The firm has a market cap of $100.89 billion, a PE ratio of 23.69, a PEG ratio of 1.20 and a beta of 0.42. The stock has a 50 day moving average of $897.30 and a 200 day moving average of $859.47. McKesson Corporation has a 12 month low of $637.00 and a 12 month high of $999.00.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The business had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities research analysts forecast that McKesson Corporation will post 39.02 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 1st. Investors of record on Monday, June 1st will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio is presently 9.43%.

Key Stories Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson sold its stake in Medical‑Surgical Solutions, a move that could unlock cash and simplify the company’s portfolio — potentially supporting buybacks or redeployment of capital. McKesson sells stake in Medical-Surgical Solutions
• Positive Sentiment: McKesson Canada secured national distribution for naturemary, expanding reach into thousands of pharmacies — a small but constructive revenue/market-access win in consumer and retail channels. naturemary Secures National Distribution with McKesson Canada, Unlocking Access to Thousands of Pharmacies
• Positive Sentiment: McKesson put a new $5.0 billion senior unsecured revolving credit facility in place, strengthening liquidity and debt flexibility ahead of potential strategic investments or cash-return programs. McKesson Secures New $5 Billion Revolving Credit Facility
• Neutral Sentiment: Analysts are re‑weighing McKesson’s valuation relative to its biosimilars/co‑manufacturing optionality; fair value estimates moved only marginally, but individual price targets diverge — highlights evolving thesis but no consensus catalyst yet. How The Narrative On McKesson (MCK) Is Shifting Around Biosimilars And Valuation Premium
• Neutral Sentiment: Investor pieces pitching McKesson as a way to play GLP‑1 channel growth highlight upside scenarios but are speculative and unlikely to move fundamentals immediately. GLP-1 trade? McKesson is your stock, this investor says
• Neutral Sentiment: Reports that lawmakers have been increasing holdings in McKesson attracted press attention — notable for optics but not a direct operational driver. Lawmakers increase stakes in McKesson, Boeing, Alphabet amid scrutiny
• Negative Sentiment: Market coverage noted McKesson fell more steeply than the broader market today, reflecting investor selling pressure and concerns over the stock’s premium to historical averages. McKesson (MCK) Falls More Steeply Than Broader Market: What Investors Need to Know
• Negative Sentiment: Competitor coverage (William Blair initiating Cardinal Health at Outperform) highlights investor appetite for distributor exposure elsewhere, which could pressure McKesson’s multiple if flows shift to peers. William Blair Initiates Cardinal Health at Outperform: Is the Pharma Distributor a Stealth Compounder?

Analyst Ratings Changes

A number of research analysts recently commented on the company. Weiss Ratings cut McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a report on Thursday, February 5th. UBS Group cut their price objective on shares of McKesson from $1,012.00 to $1,000.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Robert W. Baird set a $968.00 target price on shares of McKesson in a report on Wednesday, January 14th. JPMorgan Chase & Co. upped their target price on shares of McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Finally, Barclays raised their target price on shares of McKesson from $960.00 to $1,050.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, McKesson presently has an average rating of “Moderate Buy” and a consensus target price of $972.27.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.